10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ARCT (Arcturus Therapeutics Holdings Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Arcturus Therapeutics Holdings Inc together

I guess you are interested in Arcturus Therapeutics Holdings Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Arcturus Therapeutics Holdings Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – Arcturus Therapeutics Holdings Inc’s Price Targets

I'm going to help you getting a better view of Arcturus Therapeutics Holdings Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Arcturus Therapeutics Holdings Inc

I send you an email if I find something interesting about Arcturus Therapeutics Holdings Inc.

1. Quick Overview

1.1. Quick analysis of Arcturus Therapeutics Holdings Inc (30 sec.)










1.2. What can you expect buying and holding a share of Arcturus Therapeutics Holdings Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$8.51
Expected worth in 1 year
$7.50
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$-1.01
Return On Investment
-5.9%

For what price can you sell your share?

Current Price per Share
$17.32
Expected price per share
$11.27 - $21.26
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Arcturus Therapeutics Holdings Inc (5 min.)




Live pricePrice per Share (EOD)
$17.32
Intrinsic Value Per Share
$-10.36 - $62.39
Total Value Per Share
$-1.85 - $70.90

2.2. Growth of Arcturus Therapeutics Holdings Inc (5 min.)




Is Arcturus Therapeutics Holdings Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$231m$270.2m-$28.3m-11.7%

How much money is Arcturus Therapeutics Holdings Inc making?

Current yearPrevious yearGrowGrow %
Making money-$15m-$17.9m$2.9m19.6%
Net Profit Margin-60.3%-50.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Arcturus Therapeutics Holdings Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#226 / 863

Most Revenue
#192 / 863

Most Profit
#595 / 863

Most Efficient
#423 / 863
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Arcturus Therapeutics Holdings Inc?

Welcome investor! Arcturus Therapeutics Holdings Inc's management wants to use your money to grow the business. In return you get a share of Arcturus Therapeutics Holdings Inc.

First you should know what it really means to hold a share of Arcturus Therapeutics Holdings Inc. And how you can make/lose money.

Speculation

The Price per Share of Arcturus Therapeutics Holdings Inc is $17.32. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Arcturus Therapeutics Holdings Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Arcturus Therapeutics Holdings Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $8.51. Based on the TTM, the Book Value Change Per Share is $-0.25 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Arcturus Therapeutics Holdings Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.34-2.0%-0.55-3.2%-0.66-3.8%-0.68-3.9%-1.01-5.8%-0.61-3.5%
Usd Book Value Change Per Share-0.10-0.6%-0.25-1.5%-0.24-1.4%0.191.1%0.251.5%0.181.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.10-0.6%-0.25-1.5%-0.24-1.4%0.191.1%0.251.5%0.181.0%
Usd Price Per Share13.01-15.95-28.80-21.95-27.62-17.85-
Price to Earnings Ratio-9.62--10.35--11.78--7.84--7.38--10.29-
Price-to-Total Gains Ratio-130.55--0.12--218.55--74.47--51.54--40.55-
Price to Book Ratio1.53-1.77-2.90-2.32-2.87-5.45-
Price-to-Total Gains Ratio-130.55--0.12--218.55--74.47--51.54--40.55-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share17.32
Number of shares57
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.250.25
Usd Total Gains Per Share-0.250.25
Gains per Quarter (57 shares)-14.4514.44
Gains per Year (57 shares)-57.7957.78
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-58-6805848
20-116-1260116106
30-173-1840173164
40-231-2420231222
50-289-3000289280
60-347-3580347338
70-405-4160404396
80-462-4740462454
90-520-5320520512
100-578-5900578570

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%2.038.00.05.0%2.049.00.03.9%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%9.030.01.022.5%12.036.03.023.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.051.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%9.030.01.022.5%12.036.03.023.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Arcturus Therapeutics Holdings Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.100-0.253+154%-0.245+146%0.185-154%0.253-139%0.177-156%
Book Value Per Share--8.5098.909-4%9.954-15%9.450-10%9.646-12%5.528+54%
Current Ratio--5.9015.245+13%4.060+45%4.385+35%5.092+16%7.764-24%
Debt To Asset Ratio--0.2530.285-11%0.361-30%0.344-26%0.342-26%0.347-27%
Debt To Equity Ratio--0.3390.400-15%0.566-40%0.541-37%0.549-38%0.841-60%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--471530045.000557853252.500-15%916866850.000-49%738114903.750-36%934204472.000-50%591926552.500-20%
Eps---0.338-0.554+64%-0.663+96%-0.680+101%-1.013+200%-0.608+80%
Ev To Ebitda Ratio---10.148-11.031+9%-16.694+65%-9.482-7%-9.108-10%-51.277+405%
Ev To Sales Ratio--4.1654.898-15%6.769-38%7.046-41%49.512-92%37.821-89%
Free Cash Flow Per Share---0.212-0.595+181%-0.651+207%-0.030-86%-0.478+125%-0.313+48%
Free Cash Flow To Equity Per Share---0.754-0.583-23%-0.573-24%-0.094-88%0.219-445%0.225-435%
Gross Profit Margin--1.0001.0000%1.030-3%1.010-1%1.006-1%1.0030%
Intrinsic Value_10Y_max--62.394----------
Intrinsic Value_10Y_min---10.359----------
Intrinsic Value_1Y_max--0.805----------
Intrinsic Value_1Y_min---1.223----------
Intrinsic Value_3Y_max--6.570----------
Intrinsic Value_3Y_min---3.536----------
Intrinsic Value_5Y_max--17.340----------
Intrinsic Value_5Y_min---5.679----------
Market Cap470315940.000+25%353280045.000432978502.500-18%782049600.000-55%596063903.750-41%749898672.000-53%484572052.500-27%
Net Profit Margin---0.324-0.603+86%-0.509+57%-0.929+187%-6.370+1864%-3.862+1091%
Operating Margin----0.4350%-0.4910%-0.8590%-6.2840%-3.7880%
Operating Ratio--1.4101.494-6%1.250+13%2.640-47%12.668-89%7.900-82%
Pb Ratio2.036+25%1.5291.770-14%2.896-47%2.320-34%2.866-47%5.451-72%
Pe Ratio-12.808-33%-9.621-10.348+8%-11.782+22%-7.839-19%-7.380-23%-10.289+7%
Price Per Share17.320+25%13.01015.945-18%28.800-55%21.951-41%27.616-53%17.845-27%
Price To Free Cash Flow Ratio-20.431-33%-15.347-107.436+600%-51.282+234%-53.082+246%-36.915+141%-23.168+51%
Price To Total Gains Ratio-173.805-33%-130.554-0.119-100%-218.546+67%-74.471-43%-51.539-61%-40.548-69%
Quick Ratio--4.5944.202+9%3.445+33%3.761+22%4.696-2%10.985-58%
Return On Assets---0.030-0.044+50%-0.043+44%-0.018-38%-0.051+73%-0.074+149%
Return On Equity---0.040-0.063+58%-0.067+69%-0.029-26%-0.082+106%-0.153+284%
Total Gains Per Share---0.100-0.253+154%-0.245+146%0.185-154%0.253-139%0.177-156%
Usd Book Value--231053000.000241914000.000-4%270282500.000-15%256599000.000-10%261921450.000-12%150097750.000+54%
Usd Book Value Change Per Share---0.100-0.253+154%-0.245+146%0.185-154%0.253-139%0.177-156%
Usd Book Value Per Share--8.5098.909-4%9.954-15%9.450-10%9.646-12%5.528+54%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--471530045.000557853252.500-15%916866850.000-49%738114903.750-36%934204472.000-50%591926552.500-20%
Usd Eps---0.338-0.554+64%-0.663+96%-0.680+101%-1.013+200%-0.608+80%
Usd Free Cash Flow---5755000.000-16167553.000+181%-17684633.750+207%-804812.250-86%-12966987.350+125%-8493068.675+48%
Usd Free Cash Flow Per Share---0.212-0.595+181%-0.651+207%-0.030-86%-0.478+125%-0.313+48%
Usd Free Cash Flow To Equity Per Share---0.754-0.583-23%-0.573-24%-0.094-88%0.219-445%0.225-435%
Usd Market Cap470315940.000+25%353280045.000432978502.500-18%782049600.000-55%596063903.750-41%749898672.000-53%484572052.500-27%
Usd Price Per Share17.320+25%13.01015.945-18%28.800-55%21.951-41%27.616-53%17.845-27%
Usd Profit---9180000.000-15041000.000+64%-17990500.000+96%-4256333.333-54%-19019050.000+107%-12321275.000+34%
Usd Revenue--28301000.00029374500.000-4%36757000.000-23%43936500.000-36%28825250.000-2%16557325.000+71%
Usd Total Gains Per Share---0.100-0.253+154%-0.245+146%0.185-154%0.253-139%0.177-156%
 EOD+5 -3MRQTTM+21 -15YOY+21 -163Y+11 -265Y+16 -2110Y+19 -18

3.3 Fundamental Score

Let's check the fundamental score of Arcturus Therapeutics Holdings Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-12.808
Price to Book Ratio (EOD)Between0-12.036
Net Profit Margin (MRQ)Greater than0-0.324
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.594
Current Ratio (MRQ)Greater than15.901
Debt to Asset Ratio (MRQ)Less than10.253
Debt to Equity Ratio (MRQ)Less than10.339
Return on Equity (MRQ)Greater than0.15-0.040
Return on Assets (MRQ)Greater than0.05-0.030
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Arcturus Therapeutics Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.489
Ma 20Greater thanMa 5017.612
Ma 50Greater thanMa 10015.314
Ma 100Greater thanMa 20013.878
OpenGreater thanClose17.650
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2025-08-23 10:36:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Arcturus Therapeutics Holdings Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Arcturus Therapeutics Holdings Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -32.4% means that $-0.32 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is -32.4%. The company is making a huge loss. -2
  • The TTM is -60.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-32.4%TTM-60.3%+27.8%
TTM-60.3%YOY-50.9%-9.3%
TTM-60.3%5Y-637.0%+576.7%
5Y-637.0%10Y-386.2%-250.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-32.4%-73.5%+41.1%
TTM-60.3%-154.3%+94.0%
YOY-50.9%-207.9%+157.0%
3Y-92.9%-272.9%+180.0%
5Y-637.0%-345.5%-291.5%
10Y-386.2%-504.5%+118.3%
4.3.1.2. Return on Assets

Shows how efficient Arcturus Therapeutics Holdings Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Arcturus Therapeutics Holdings Inc to the Biotechnology industry mean.
  • -3.0% Return on Assets means that Arcturus Therapeutics Holdings Inc generated $-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is -3.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.0%TTM-4.4%+1.5%
TTM-4.4%YOY-4.3%-0.2%
TTM-4.4%5Y-5.1%+0.7%
5Y-5.1%10Y-7.4%+2.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.0%-11.8%+8.8%
TTM-4.4%-11.6%+7.2%
YOY-4.3%-11.0%+6.7%
3Y-1.8%-11.9%+10.1%
5Y-5.1%-11.5%+6.4%
10Y-7.4%-13.6%+6.2%
4.3.1.3. Return on Equity

Shows how efficient Arcturus Therapeutics Holdings Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Arcturus Therapeutics Holdings Inc to the Biotechnology industry mean.
  • -4.0% Return on Equity means Arcturus Therapeutics Holdings Inc generated $-0.04 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is -4.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -6.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.0%TTM-6.3%+2.3%
TTM-6.3%YOY-6.7%+0.4%
TTM-6.3%5Y-8.2%+1.9%
5Y-8.2%10Y-15.3%+7.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.0%-13.7%+9.7%
TTM-6.3%-14.6%+8.3%
YOY-6.7%-15.0%+8.3%
3Y-2.9%-16.4%+13.5%
5Y-8.2%-16.9%+8.7%
10Y-15.3%-19.0%+3.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Arcturus Therapeutics Holdings Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Arcturus Therapeutics Holdings Inc is operating .

  • Measures how much profit Arcturus Therapeutics Holdings Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Arcturus Therapeutics Holdings Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-43.5%+43.5%
TTM-43.5%YOY-49.1%+5.7%
TTM-43.5%5Y-628.4%+584.9%
5Y-628.4%10Y-378.8%-249.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--153.1%+153.1%
TTM-43.5%-247.8%+204.3%
YOY-49.1%-244.8%+195.7%
3Y-85.9%-256.2%+170.3%
5Y-628.4%-340.5%-287.9%
10Y-378.8%-503.1%+124.3%
4.3.2.2. Operating Ratio

Measures how efficient Arcturus Therapeutics Holdings Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.41 means that the operating costs are $1.41 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 1.410. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.494. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.410TTM1.494-0.084
TTM1.494YOY1.250+0.244
TTM1.4945Y12.668-11.174
5Y12.66810Y7.900+4.768
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4101.859-0.449
TTM1.4942.752-1.258
YOY1.2502.941-1.691
3Y2.6403.642-1.002
5Y12.6684.701+7.967
10Y7.9006.681+1.219
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Arcturus Therapeutics Holdings Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Arcturus Therapeutics Holdings Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.90 means the company has $5.90 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 5.901. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.245. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.901TTM5.245+0.657
TTM5.245YOY4.060+1.185
TTM5.2455Y5.092+0.153
5Y5.09210Y7.764-2.672
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.9013.457+2.444
TTM5.2453.689+1.556
YOY4.0604.093-0.033
3Y4.3854.571-0.186
5Y5.0925.722-0.630
10Y7.7646.137+1.627
4.4.3.2. Quick Ratio

Measures if Arcturus Therapeutics Holdings Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Arcturus Therapeutics Holdings Inc to the Biotechnology industry mean.
  • A Quick Ratio of 4.59 means the company can pay off $4.59 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 4.594. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.202. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.594TTM4.202+0.391
TTM4.202YOY3.445+0.757
TTM4.2025Y4.696-0.494
5Y4.69610Y10.985-6.289
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.5942.940+1.654
TTM4.2023.288+0.914
YOY3.4453.896-0.451
3Y3.7614.373-0.612
5Y4.6965.800-1.104
10Y10.9856.520+4.465
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Arcturus Therapeutics Holdings Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Arcturus Therapeutics Holdings Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Arcturus Therapeutics Holdings Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.25 means that Arcturus Therapeutics Holdings Inc assets are financed with 25.3% credit (debt) and the remaining percentage (100% - 25.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 0.253. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.285. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.253TTM0.285-0.032
TTM0.285YOY0.361-0.076
TTM0.2855Y0.342-0.057
5Y0.34210Y0.347-0.005
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2530.339-0.086
TTM0.2850.356-0.071
YOY0.3610.334+0.027
3Y0.3440.3440.000
5Y0.3420.351-0.009
10Y0.3470.378-0.031
4.5.4.2. Debt to Equity Ratio

Measures if Arcturus Therapeutics Holdings Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Arcturus Therapeutics Holdings Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 33.9% means that company has $0.34 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The MRQ is 0.339. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.400. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.339TTM0.400-0.062
TTM0.400YOY0.566-0.166
TTM0.4005Y0.549-0.149
5Y0.54910Y0.841-0.292
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3390.393-0.054
TTM0.4000.439-0.039
YOY0.5660.435+0.131
3Y0.5410.462+0.079
5Y0.5490.463+0.086
10Y0.8410.511+0.330
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Arcturus Therapeutics Holdings Inc generates.

  • Above 15 is considered overpriced but always compare Arcturus Therapeutics Holdings Inc to the Biotechnology industry mean.
  • A PE ratio of -9.62 means the investor is paying $-9.62 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The EOD is -12.808. Based on the earnings, the company is expensive. -2
  • The MRQ is -9.621. Based on the earnings, the company is expensive. -2
  • The TTM is -10.348. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.808MRQ-9.621-3.187
MRQ-9.621TTM-10.348+0.727
TTM-10.348YOY-11.782+1.433
TTM-10.3485Y-7.380-2.968
5Y-7.38010Y-10.289+2.909
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-12.808-2.447-10.361
MRQ-9.621-2.328-7.293
TTM-10.348-2.662-7.686
YOY-11.782-3.729-8.053
3Y-7.839-3.747-4.092
5Y-7.380-6.305-1.075
10Y-10.289-6.948-3.341
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The EOD is -20.431. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -15.347. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -107.436. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-20.431MRQ-15.347-5.084
MRQ-15.347TTM-107.436+92.089
TTM-107.436YOY-51.282-56.154
TTM-107.4365Y-36.915-70.521
5Y-36.91510Y-23.168-13.747
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-20.431-3.310-17.121
MRQ-15.347-2.934-12.413
TTM-107.436-3.859-103.577
YOY-51.282-4.296-46.986
3Y-53.082-5.225-47.857
5Y-36.915-8.425-28.490
10Y-23.168-9.639-13.529
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Arcturus Therapeutics Holdings Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.53 means the investor is paying $1.53 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Arcturus Therapeutics Holdings Inc:

  • The EOD is 2.036. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.529. Based on the equity, the company is underpriced. +1
  • The TTM is 1.770. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.036MRQ1.529+0.507
MRQ1.529TTM1.770-0.241
TTM1.770YOY2.896-1.126
TTM1.7705Y2.866-1.097
5Y2.86610Y5.451-2.585
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.0362.233-0.197
MRQ1.5292.000-0.471
TTM1.7702.205-0.435
YOY2.8962.413+0.483
3Y2.3202.571-0.251
5Y2.8663.756-0.890
10Y5.4514.451+1.000
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Arcturus Therapeutics Holdings Inc.

4.8.1. Institutions holding Arcturus Therapeutics Holdings Inc

Institutions are holding 89.253% of the shares of Arcturus Therapeutics Holdings Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Federated Hermes Inc17.29060.1072469406000
2025-03-31BlackRock Inc10.16640.00062759970-229631-7.681
2025-03-31Nikko Asset Management Americas Inc7.09480.26271926084-138966-6.7294
2025-06-30Sumitomo Mitsui Trust Group Inc6.74990.01491832467-93617-4.8605
2025-06-30Vanguard Group Inc6.66780.00041810165612373.5014
2025-06-30ARK Investment Management LLC6.31740.16361715040-293440-14.6101
2025-03-31State Street Corp4.71660.00061280451-45707-3.4466
2025-03-31Balyasny Asset Management LLC3.45580.016493819038942970.9651
2025-03-31Schonfeld Strategic Advisors LLC3.04170.0527825766-23315-2.7459
2025-03-31Woodline Partners LP2.87480.0538780442-26470-3.2804
2025-06-30Goldman Sachs Group Inc2.28470.001162025711054521.6877
2025-06-30Dimensional Fund Advisors, Inc.2.14480.0018582279-34355-5.5714
2025-03-31Geode Capital Management, LLC2.09820.0005569620146362.6372
2025-03-31Morgan Stanley - Brokerage Accounts2.03230.0004551726132322.4572
2025-03-31Millennium Management LLC1.70140.00264619074619070
2025-03-31Bank of America Corp1.06940.0003290331262619947.6725
2025-03-31Empire Life Investments Inc0.97580.1826264909-14554-5.2078
2025-03-31FMR Inc0.96510.0002262010-186801-41.6213
2025-03-31Northern Trust Corp0.92110.0004250051-6281-2.4503
2025-03-31JPMorgan Chase & Co0.85650.0002232512-3856-1.6314
Total 83.42510.86322648237+216612+1.0%

4.9.2. Funds holding Arcturus Therapeutics Holdings Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30Federated Hermes Kaufmann R8.97260.6358243588000
2025-06-30Federated Hermes Kaufmann Growth8.97260.6419243588000
2025-06-30Federated Hermes Kaufmann Small Cap Grow8.09640.8914219802000
2025-06-30Federated Hermes Kaufmann Small Cap A8.09640.8774219802000
2025-03-31ARK Genomic Revolution7.28252.18071977066682213.5739
2025-07-31ARK Genomic Revolution ETF6.11422.06261659873-9955-0.5962
2025-06-30Nikko AM ARK Pstv Chg Innovt P JPY Acc5.92480.94591608466-56860-3.4143
2025-06-30Vanguard Total Stock Mkt Idx Inv2.66950.000572472200
2025-07-31iShares Russell 2000 ETF2.23980.0123608060-11550-1.8641
2025-07-31SPDR® S&P Biotech ETF1.68950.1165458662137353.087
2025-06-30Vanguard Institutional Extnd Mkt Idx Tr1.36780.0042371333-38166-9.3202
2025-06-30Vanguard Explorer Inv0.9010.01582445936009032.5686
2025-05-31Fidelity Small Cap Index0.85420.0117231899-4228-1.7906
2025-07-31JPM Thematics Genetic Thrps C2 dist USD0.67050.6297182024-1395-0.7606
2025-06-30Fidelity Select Biotechnology0.66170.062417963000
2025-07-31State St Russell Sm/Mid Cp® Indx SL Cl I0.62840.004817058500
2025-06-30Empire Life American Value - Class A0.59670.250316199500
2025-07-31iShares Biotechnology ETF0.55660.033915110112880.8597
2025-06-30BlackRock Advantage Small Cap Core Instl0.52970.0455143790-1511-1.0399
2025-06-30Fidelity Extended Market Index0.50140.0045136126-355-0.2601
Total 67.32639.427818277725+19314+0.1%

5.3. Insider Transactions

Insiders are holding 7.882% of the shares of Arcturus Therapeutics Holdings Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-10-15Pad ChivukulaSELL1200020.76
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-06-302024-09-302024-12-312025-03-312025-06-30
Income Tax Expense  -150-67-217213-4-16,843-16,84716,8514



5.2. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets309,270
Total Liabilities78,217
Total Stockholder Equity231,053
 As reported
Total Liabilities 78,217
Total Stockholder Equity+ 231,053
Total Assets = 309,270

Assets

Total Assets309,270
Total Current Assets274,503
Long-term Assets34,767
Total Current Assets
Cash And Cash Equivalents 196,467
Net Receivables 17,204
Other Current Assets 60,832
Total Current Assets  (as reported)274,503
Total Current Assets  (calculated)274,503
+/-0
Long-term Assets
Property Plant Equipment 32,882
Long-term Assets Other 1,885
Long-term Assets  (as reported)34,767
Long-term Assets  (calculated)34,767
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities46,515
Long-term Liabilities31,702
Total Stockholder Equity231,053
Total Current Liabilities
Accounts payable 10,623
Other Current Liabilities 24,629
Total Current Liabilities  (as reported)46,515
Total Current Liabilities  (calculated)35,252
+/- 11,263
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt26,964
Long-term Liabilities  (as reported)31,702
Long-term Liabilities  (calculated)26,964
+/- 4,738
Total Stockholder Equity
Common Stock27
Retained Earnings -472,063
Other Stockholders Equity 703,089
Total Stockholder Equity (as reported)231,053
Total Stockholder Equity (calculated)231,053
+/-0
Other
Capital Stock27
Cash and Short Term Investments 196,467
Common Stock Shares Outstanding 27,129
Current Deferred Revenue11,263
Liabilities and Stockholders Equity 309,270
Net Debt -173,534
Net Invested Capital 231,053
Net Working Capital 227,988
Property Plant and Equipment Gross 46,273
Short Long Term Debt Total 22,933



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-30
> Total Assets 
0
0
201
0
21,704
19,805
50,324
45,603
40,171
30,863
22,318
0
41,624
37,647
71,683
67,097
62,689
55,912
51,568
46,419
42,351
40,586
52,024
0
44,322
37,115
44,198
44,419
70,940
87,215
82,143
72,104
149,935
322,520
476,456
481,468
448,813
434,536
392,814
341,988
337,014
293,627
450,387
470,863
430,646
457,650
429,402
418,849
388,608
370,654
344,069
331,785
309,270
309,270331,785344,069370,654388,608418,849429,402457,650430,646470,863450,387293,627337,014341,988392,814434,536448,813481,468476,456322,520149,93572,10482,14387,21570,94044,41944,19837,11544,322052,02440,58642,35146,41951,56855,91262,68967,09771,68337,64741,624022,31830,86340,17145,60350,32419,80521,704020100
   > Total Current Assets 
0
0
180
0
21,680
19,722
50,218
45,416
39,959
30,652
22,126
0
41,427
37,363
52,346
54,764
54,358
52,626
51,299
46,173
42,121
40,406
50,868
48,573
41,682
34,401
41,828
36,606
63,338
79,408
74,290
63,759
142,000
314,100
467,789
469,996
438,038
420,966
378,961
327,005
291,505
246,680
403,333
424,555
385,244
393,268
386,590
375,788
347,008
330,821
305,979
278,794
274,503
274,503278,794305,979330,821347,008375,788386,590393,268385,244424,555403,333246,680291,505327,005378,961420,966438,038469,996467,789314,100142,00063,75974,29079,40863,33836,60641,82834,40141,68248,57350,86840,40642,12146,17351,29952,62654,35854,76452,34637,36341,427022,12630,65239,95945,41650,21819,72221,680018000
       Cash And Cash Equivalents 
0
0
97
0
17,593
4,540
22,095
10,392
6,912
2,714
2,176
0
8,570
9,970
16,658
13,487
15,093
4,375
2,304
4,674
3,568
3,007
24,965
-48,573
39,777
30,331
36,709
31,220
55,840
74,172
71,353
59,471
136,111
307,023
462,895
466,839
433,574
413,880
370,492
319,678
283,491
237,676
391,883
327,935
323,471
311,918
347,005
288,396
315,329
237,178
237,028
216,948
196,467
196,467216,948237,028237,178315,329288,396347,005311,918323,471327,935391,883237,676283,491319,678370,492413,880433,574466,839462,895307,023136,11159,47171,35374,17255,84031,22036,70930,33139,777-48,57324,9653,0073,5684,6742,3044,37515,09313,48716,6589,9708,57002,1762,7146,91210,39222,0954,54017,59309700
       Short-term Investments 
0
0
0
0
4,000
15,000
28,008
34,033
32,025
26,724
19,522
0
32,523
25,537
34,022
39,739
37,989
46,972
47,938
40,578
37,620
36,814
23,608
97,146
10,455
2,499
0
0
0
0
0
0
0
0
0
1,248
920
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000009201,2480000000002,49910,45597,14623,60836,81437,62040,57847,93846,97237,98939,73934,02225,53732,523019,52226,72432,02534,03328,00815,0004,0000000
       Net Receivables 
0
0
10
0
87
182
46
991
1,022
0
117
0
0
0
328
0
0
0
521
0
0
0
480
0
1,371
1,123
4,481
4,457
5,817
2,625
2,179
2,351
2,829
2,447
2,125
2,007
2,163
2,015
3,367
3,691
2,247
2,044
2,764
92,483
2,799
38,220
32,064
27,057
24,085
30,199
3,974
14,572
17,204
17,20414,5723,97430,19924,08527,05732,06438,2202,79992,4832,7642,0442,2473,6913,3672,0152,1632,0072,1252,4472,8292,3512,1792,6255,8174,4574,4811,1231,371048000052100032800011701,022991461828701000
       Other Current Assets 
0
0
73
0
174
364
69
1,982
2,044
1,214
311
0
334
1,856
1,338
1,538
1,276
1,279
536
921
933
585
1,815
0
534
448
638
929
1,681
2,611
1,516
1,937
6,120
9,260
5,538
2,300
2,301
5,071
10,204
7,272
11,534
13,920
8,686
4,137
58,974
8,130
62,521
5,335
62,594
63,444
64,977
47,274
60,832
60,83247,27464,97763,44462,5945,33562,5218,13058,9744,1378,68613,92011,5347,27210,2045,0712,3012,3005,5389,2606,1201,9371,5162,6111,68192963844853401,8155859339215361,2791,2761,5381,3381,85633403111,2142,0441,9826936417407300
   > Long-term Assets 
0
0
21
0
24
83
106
187
212
211
192
0
197
284
19,337
12,333
8,331
3,286
269
246
230
180
1,156
-48,573
2,640
2,714
2,370
7,813
7,602
7,807
7,853
8,345
7,935
8,420
8,667
11,472
10,775
13,570
13,853
14,983
45,509
46,947
47,054
46,308
45,402
64,382
42,812
43,061
41,600
39,833
38,090
52,991
34,767
34,76752,99138,09039,83341,60043,06142,81264,38245,40246,30847,05446,94745,50914,98313,85313,57010,77511,4728,6678,4207,9358,3457,8537,8077,6027,8132,3702,7142,640-48,5731,1561802302462693,2868,33112,33319,3372841970192211212187106832402100
       Property Plant Equipment 
0
0
18
0
17
32
49
93
105
107
97
0
112
197
227
235
219
212
240
219
210
167
1,049
0
1,943
2,064
1,975
7,706
7,495
7,397
7,483
8,138
7,828
8,313
8,560
10,117
9,748
10,826
11,261
12,775
43,431
44,866
44,960
44,192
43,275
42,249
40,927
41,176
39,715
37,948
36,205
34,606
32,882
32,88234,60636,20537,94839,71541,17640,92742,24943,27544,19244,96044,86643,43112,77511,26110,8269,74810,1178,5608,3137,8288,1387,4837,3977,4957,7061,9752,0641,94301,0491672102192402122192352271971120971071059349321701800
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
590
543
288
0
0
303
263
100
0
0
0
1,248
920
670
515
131
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000001315156709201,24800010026330300288543590000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
70
27
20
13
107
0
107
107
107
107
107
107
107
107
107
107
5,289
107
107
2,074
2,077
2,077
2,078
2,081
0
0
2,127
0
0
0
0
0
0
0
0
000000002,127002,0812,0782,0772,0772,0741071075,289107107107107107107107107107107010713202770000000000000000000
> Total Liabilities 
0
0
768
0
343
1,281
1,636
3,346
4,753
4,905
2,375
0
2,864
2,564
2,352
2,110
2,907
3,295
4,340
2,190
1,657
2,296
18,230
0
26,527
22,964
30,556
38,065
49,322
51,320
56,351
55,122
56,512
60,890
79,903
128,861
143,165
175,410
164,603
157,239
166,297
147,960
180,075
141,615
145,471
177,588
150,889
154,877
130,025
108,788
103,091
98,026
78,217
78,21798,026103,091108,788130,025154,877150,889177,588145,471141,615180,075147,960166,297157,239164,603175,410143,165128,86179,90360,89056,51255,12256,35151,32049,32238,06530,55622,96426,527018,2302,2961,6572,1904,3403,2952,9072,1102,3522,5642,86402,3754,9054,7533,3461,6361,281343076800
   > Total Current Liabilities 
0
0
768
0
343
1,281
1,636
3,346
4,753
4,905
2,375
0
2,864
2,564
2,352
2,110
2,907
3,295
4,340
2,190
1,657
2,296
11,040
0
18,253
13,600
12,577
14,612
16,414
21,688
21,324
21,650
23,046
28,014
49,521
53,333
70,769
118,239
99,537
107,306
92,743
75,849
126,984
90,130
90,345
87,683
81,989
115,430
91,717
69,463
65,489
49,409
46,515
46,51549,40965,48969,46391,717115,43081,98987,68390,34590,130126,98475,84992,743107,30699,537118,23970,76953,33349,52128,01423,04621,65021,32421,68816,41414,61212,57713,60018,253011,0402,2961,6572,1904,3403,2952,9072,1102,3522,5642,86402,3754,9054,7533,3461,6361,281343076800
       Short-term Debt 
0
0
662
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-4,261
133
0
0
0
0
11,168
0
0
750
775
801
827
1,474
1,337
1,198
2,880
4,568
6,430
19,965
24,011
25,913
30,435
31,485
64,539
3,987
4,092
8,400
8,618
8,540
7,834
6,870
7,104
7,342
0
07,3427,1046,8707,8348,5408,6188,4004,0923,98764,53931,48530,43525,91324,01119,9656,4304,5682,8801,1981,3371,4748278017757500011,1680000133-4,26100000000000000066200
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
133
133
0
0
0
0
0
0
0
750
0
0
0
0
0
0
1,250
3,125
5,000
18,482
22,474
24,260
27,018
27,702
60,655
0
0
0
0
0
0
0
0
0
0
000000000060,65527,70227,01824,26022,47418,4825,0003,1251,2500000007500000000133133000000000000000000
       Accounts payable 
0
0
23
0
67
31
47
1,409
1,457
1,532
305
0
161
527
57
111
138
152
3,357
488
19
36
1,790
0
2,781
2,905
2,398
4,118
3,187
4,013
5,793
3,779
4,395
6,478
10,774
5,597
10,084
8,265
10,058
10,014
5,762
17,962
7,449
19,344
13,619
18,362
5,279
9,144
13,905
10,131
7,194
6,179
10,623
10,6236,1797,19410,13113,9059,1445,27918,36213,61919,3447,44917,9625,76210,01410,0588,26510,0845,59710,7746,4784,3953,7795,7934,0133,1874,1182,3982,9052,78101,79036194883,3571521381115752716103051,5321,4571,40947316702300
       Other Current Liabilities 
0
0
83
0
276
1,250
1,589
1,937
3,296
3,373
2,070
0
2,703
2,037
2,295
1,999
2,769
3,143
-3,333
1,702
1,638
2,260
2,793
0
15,472
10,695
10,179
2,016
2,722
5,875
6,307
8,301
10,546
14,640
17,759
25,232
36,184
32,393
21,986
18,317
30,197
15,850
53,701
18,832
20,678
19,671
20,108
22,258
25,102
25,526
29,256
20,796
24,629
24,62920,79629,25625,52625,10222,25820,10819,67120,67818,83253,70115,85030,19718,31721,98632,39336,18425,23217,75914,64010,5468,3016,3075,8752,7222,01610,17910,69515,47202,7932,2601,6381,702-3,3333,1432,7691,9992,2952,0372,70302,0703,3733,2961,9371,5891,25027608300
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,190
0
8,274
9,364
17,979
23,453
32,908
29,632
35,027
33,472
33,466
32,876
30,382
75,528
72,396
57,171
65,066
49,933
73,554
72,111
53,091
51,485
55,126
89,905
68,900
39,447
38,308
39,325
37,602
48,617
31,702
31,70248,61737,60239,32538,30839,44768,90089,90555,12651,48553,09172,11173,55449,93365,06657,17172,39675,52830,38232,87633,46633,47235,02729,63232,90823,45317,9799,3648,27407,1900000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,911
9,945
9,980
10,016
14,995
15,028
15,059
15,076
13,845
58,147
56,309
42,345
40,633
39,235
35,761
32,038
0
0
0
0
0
0
0
0
0
0
0
0000000000032,03835,76139,23540,63342,34556,30958,14713,84515,07615,05915,02814,99510,0169,9809,9459,91100000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,425
0
0
0
7,190
0
8,274
9,364
8,068
8,025
17,652
14,551
15,182
13,815
14,013
13,645
12,512
11,671
10,728
9,891
19,931
6,641
5,590
8,855
22,875
0
27,015
0
0
0
0
0
0
0
0
0000000027,015022,8758,8555,5906,64119,9319,89110,72811,67112,51213,64514,01313,81515,18214,55117,6528,0258,0689,3648,27407,1900003,425000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,652
14,551
15,182
13,815
14,013
13,645
12,512
11,313
9,850
8,497
19,931
6,641
5,590
5,179
0
20,569
0
0
0
0
0
0
0
0
0
00000000020,56905,1795,5906,64119,9318,4979,85011,31312,51213,64514,01313,81515,18214,55117,6520000000000000000000000000000
> Total Stockholder Equity
0
0
-567
0
21,361
18,524
48,688
42,257
35,418
25,958
19,943
0
38,760
35,083
69,331
64,987
59,782
52,617
47,228
44,229
40,694
38,290
33,794
33,794
17,795
14,151
13,642
6,354
21,618
35,895
25,792
16,982
93,423
261,630
396,553
352,607
305,648
259,126
228,211
184,749
170,717
145,667
270,312
329,248
285,175
280,062
278,513
263,972
258,583
261,866
240,978
233,759
231,053
231,053233,759240,978261,866258,583263,972278,513280,062285,175329,248270,312145,667170,717184,749228,211259,126305,648352,607396,553261,63093,42316,98225,79235,89521,6186,35413,64214,15117,79533,79433,79438,29040,69444,22947,22852,61759,78264,98769,33135,08338,760019,94325,95835,41842,25748,68818,52421,3610-56700
   Common Stock
0
0
4
0
32
32
39
39
39
39
39
0
58
58
74
74
74
74
74
74
74
74
212
0
214
214
214
214
13
15
15
15
21
25
26
26
26
26
26
26
26
26
27
27
27
27
27
27
27
27
27
27
27
272727272727272727272726262626262626262521151515132142142142140212747474747474747458580393939393932320400
   Retained Earnings Total Equity000000000-287,3870-455,488-420,222-398,659-347,490-308,827-254,743-200,162-143,816-112,712-91,708-81,445-71,668-60,679-53,2460000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-22
0
0
0
-30
0
0
0
-60
0
0
0
-111
0
5
-3
-6
-4
-3
-2
-3
33,794
2
4
-1,497
-1,669
-1,846
-2,028
-2,181
-2,363
-2,575
-2,794
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000-2,794-2,575-2,363-2,181-2,028-1,846-1,669-1,4974233,794-3-2-3-4-6-350-111000-60000-30000-2200
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
58,302
58,701
74,851
96,559
97,445
98,412
185,110
374,317
540,343
552,743
560,365
567,927
575,675
583,382
590,913
601,129
0
616,608
0
0
0
0
0
0
0
0
0
000000000616,6080601,129590,913583,382575,675567,927560,365552,743540,343374,317185,11098,41297,44596,55974,85158,70158,30200000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
7,637
0
31,231
31,523
67,383
68,718
69,659
70,685
71,472
0
100,570
101,155
140,274
141,016
141,594
142,239
142,780
143,299
143,454
143,604
56,674
0
57,189
57,796
58,302
58,701
74,851
96,559
97,445
98,412
185,110
374,317
540,343
552,743
560,365
567,927
575,675
583,382
590,913
601,129
608,426
616,608
625,085
636,194
646,352
658,628
670,455
680,641
689,758
696,615
703,089
703,089696,615689,758680,641670,455658,628646,352636,194625,085616,608608,426601,129590,913583,382575,675567,927560,365552,743540,343374,317185,11098,41297,44596,55974,85158,70158,30257,79657,189056,674143,604143,454143,299142,780142,239141,594141,016140,274101,155100,570071,47270,68569,65968,71867,38331,52331,23107,63700



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue138,389
Cost of Revenue-3,544
Gross Profit134,845134,845
 
Operating Income (+$)
Gross Profit134,845
Operating Expense-173,971
Operating Income-95,669-39,126
 
Operating Expense (+$)
Research Development195,156
Selling General Administrative52,823
Selling And Marketing Expenses0
Operating Expense173,971247,979
 
Net Interest Income (+$)
Interest Income15,195
Interest Expense-0
Other Finance Cost-0
Net Interest Income15,195
 
Pretax Income (+$)
Operating Income-95,669
Net Interest Income15,195
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-80,945-110,393
EBIT - interestExpense = -80,945
-80,945
-80,941
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-80,945-80,945
Earnings Before Interest and Taxes (EBITDA)-77,401
 
After tax Income (+$)
Income Before Tax-80,945
Tax Provision--4
Net Income From Continuing Ops-80,941-80,941
Net Income-80,941
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses177,515
Total Other Income/Expenses Net14,724-15,195
 

Technical Analysis of Arcturus Therapeutics Holdings Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Arcturus Therapeutics Holdings Inc. The general trend of Arcturus Therapeutics Holdings Inc is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Arcturus Therapeutics Holdings Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Arcturus Therapeutics Holdings Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Arcturus Therapeutics Holdings Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 19.99 < 20.92 < 21.26.

The bearish price targets are: 16.17 > 15.83 > 11.27.

Know someone who trades $ARCT? Share this with them.👇

Arcturus Therapeutics Holdings Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Arcturus Therapeutics Holdings Inc. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Arcturus Therapeutics Holdings Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Arcturus Therapeutics Holdings Inc. The current macd is 0.70200421.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Arcturus Therapeutics Holdings Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Arcturus Therapeutics Holdings Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Arcturus Therapeutics Holdings Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Arcturus Therapeutics Holdings Inc Daily Moving Average Convergence/Divergence (MACD) ChartArcturus Therapeutics Holdings Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Arcturus Therapeutics Holdings Inc. The current adx is 30.26.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Arcturus Therapeutics Holdings Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Arcturus Therapeutics Holdings Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Arcturus Therapeutics Holdings Inc. The current sar is 19.55.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Arcturus Therapeutics Holdings Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Arcturus Therapeutics Holdings Inc. The current rsi is 54.49. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Arcturus Therapeutics Holdings Inc Daily Relative Strength Index (RSI) ChartArcturus Therapeutics Holdings Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Arcturus Therapeutics Holdings Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Arcturus Therapeutics Holdings Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Arcturus Therapeutics Holdings Inc Daily Stochastic Oscillator ChartArcturus Therapeutics Holdings Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Arcturus Therapeutics Holdings Inc. The current cci is -60.84666362.

Arcturus Therapeutics Holdings Inc Daily Commodity Channel Index (CCI) ChartArcturus Therapeutics Holdings Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Arcturus Therapeutics Holdings Inc. The current cmo is 1.41794687.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Arcturus Therapeutics Holdings Inc Daily Chande Momentum Oscillator (CMO) ChartArcturus Therapeutics Holdings Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Arcturus Therapeutics Holdings Inc. The current willr is -55.76923077.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Arcturus Therapeutics Holdings Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Arcturus Therapeutics Holdings Inc Daily Williams %R ChartArcturus Therapeutics Holdings Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Arcturus Therapeutics Holdings Inc. The current atr is 1.14341913.

Arcturus Therapeutics Holdings Inc Daily Average True Range (ATR) ChartArcturus Therapeutics Holdings Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Arcturus Therapeutics Holdings Inc. The current obv is 2,459,791.

Arcturus Therapeutics Holdings Inc Daily On-Balance Volume (OBV) ChartArcturus Therapeutics Holdings Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Arcturus Therapeutics Holdings Inc. The current mfi is 39.14.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Arcturus Therapeutics Holdings Inc Daily Money Flow Index (MFI) ChartArcturus Therapeutics Holdings Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Arcturus Therapeutics Holdings Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-09-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-12STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Arcturus Therapeutics Holdings Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Arcturus Therapeutics Holdings Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.489
Ma 20Greater thanMa 5017.612
Ma 50Greater thanMa 10015.314
Ma 100Greater thanMa 20013.878
OpenGreater thanClose17.650
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Arcturus Therapeutics Holdings Inc with someone you think should read this too:
  • Are you bullish or bearish on Arcturus Therapeutics Holdings Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Arcturus Therapeutics Holdings Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Arcturus Therapeutics Holdings Inc

I send you an email if I find something interesting about Arcturus Therapeutics Holdings Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Arcturus Therapeutics Holdings Inc.

Receive notifications about Arcturus Therapeutics Holdings Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.